You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和譽-B(02256.HK)收到默克對Pimicotinib獨家許可協議首付款7,000萬美元
阿思達克 02-06 08:24
和譽-B(02256.HK)公佈,其附屬和譽醫藥就其去年12月與默克(MRK.US)對Pimicotinib (ABSK021)達成的獨家許可協議,已收到首付款7,000萬美元,標誌着該合作的第一步圓滿完成。 公司認爲,該首付款的到賬,進一步充盈了現金儲備,也將爲後續管線研發和國際化戰略的推進提供助力。 Pimicotinib是和譽醫藥獨立自主研發的一款全新的口服、高選擇性、高活性CSF-1R小分子抑制劑,已獲得中美歐三地突破性治療藥物認定和優先藥物認定、美國快速通道認定、歐洲孤兒藥資格認定用於治療不可手術的腱鞘鉅細胞瘤(TGCT),該項研究是TGCT疾病領域首個在中國、美國、加拿大和歐洲同步開展的全球III期研究。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account